Skip to content
HowShorted

Acurx Pharmaceuticals, Inc. short interest in 2024

In 2024, Acurx Pharmaceuticals, Inc.'s disclosed short interest ran from 1.77% of shares outstanding on 12 Jan 2024 to 2.73% on 31 Dec 2024, a change of +0.96 percentage points. The year's high was 4.37% on 31 May 2024 and its low 1.77% on 12 Jan 2024, averaging 2.98% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 24.34 days on 14 Jun 2024. Full history: Acurx Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Acurx Pharmaceuticals, Inc. in 2024

2024 in figures

Start of year
1.77% (12 Jan 2024)
End of year
2.73% (31 Dec 2024)
Change
+0.96 pp
High
4.37% (31 May 2024)
Low
1.77% (12 Jan 2024)
Average
2.98%
Highest days to cover
24.34 (14 Jun 2024)
SEC filings marked
8

Every report in 2024

Acurx Pharmaceuticals, Inc. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 20241.77%1.29
31 Jan 20242.50%1.00
15 Feb 20242.19%2.92
29 Feb 20242.12%2.62
15 Mar 20241.87%6.7110-K filed
28 Mar 20242.14%2.50results (8-K)
15 Apr 20243.68%7.73
30 Apr 20243.91%7.27
15 May 20243.78%12.3310-Q filed, results (8-K)
31 May 20244.37%8.65
14 Jun 20244.20%24.34
28 Jun 20243.90%20.30
15 Jul 20243.56%17.66
31 Jul 20242.95%4.04
15 Aug 20242.71%8.9010-Q filed, results (8-K)
30 Aug 20242.79%7.41
13 Sep 20242.94%7.76
30 Sep 20243.03%8.51
15 Oct 20243.09%15.53
31 Oct 20242.92%12.37
15 Nov 20242.63%12.2610-Q filed, results (8-K)
29 Nov 20242.75%1.59
13 Dec 20242.97%1.59
31 Dec 20242.73%4.28

See also: Acurx Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.